Application of Quality by Design (QbD) in the Development and Industrial Scale-Up of Solid Oral Dosage Forms: A Comprehensive Review

Abstract

Quality by Design (QbD) has shifted the pharmaceutical paradigm fromretrospective testing to a proactive, science-based, and risk-managedapproach that ensures product quality is built-in by design. Thiscomprehensive review examines the strategic application of QbD principlesacross the entire lifecycle of solid oral dosage forms, emphasizing the criticaltransition from laboratory-scale formulation development to full-scalecommercial manufacturing. We dissect the core components of the QbDframework, including the definition of the Quality Target Product Profile(QTPP), identification of Critical Quality Attributes (CQAs), screening ofCritical Material Attributes (CMAs) and Critical Process Parameters (CPPs),and the establishment of a robust Design Space. Special attention is dedicated to the technical challenges encountered during industrialscale-up—such as segregation, tablet capping, weight variation, and dissolution rate shifts—and how mathematical modeling, Process Analytical Technology (PAT), and multivariate data analysis (MVDA) can mitigate these scale-dependent variations. Through quantitative comparative analysis and detailed industrial case studies across standard operations like high-shear wet granulation, fluid bed drying, and roller compaction, this paper illuminates the mechanistic correlations that govern process dynamics. Ultimately, the integration of QbD not only streamlines regulatory pathways but significantly enhances batch consistency, reduces waste, and establishes a foundation for continuous manufacturing innovation.  KEYWORDS: Quality by Design (QbD); Solid Oral Dosage Forms;Industrial Scale-Up; Process Analytical Technology (PAT); Design Space;Critical Process Parameters (CPPs); Critical Material Attributes (CMAs);Risk Assessment.